(QLTI) The 2023 Series Trust II - Overview

The 2023 ETF Series Trust II (NASDAQ: QLTI) is an actively managed exchange-traded fund that targets non-U.S. large-cap growth equities deemed “high quality” by its adviser, Grantham, Mayo, Van Otterloo & Co. (GMO). In addition to these equities, the fund may allocate assets to the GMO U.S. Treasury Fund, other GMO-advised mutual funds, or to money-market-style instruments, making it a non-diversified vehicle that blends equity exposure with cash-equivalent holdings.

Key quantitative points (as of the latest filing) include an expense ratio of roughly 0.55 % p.a., assets under management (AUM) near $150 million, and a 12-month trailing return of about +8 % vs. the MSCI World ex-USA Growth index’s +6 % over the same period. The fund’s top sector allocations are typically technology (≈30 %), consumer discretionary (≈20 %), and health care (≈15 %). Currency exposure is a material driver, with the Euro and Yen accounting for the bulk of foreign-exchange risk, which can amplify or dampen performance depending on FX movements.

Given the fund’s focus on high-quality non-U.S. growth stocks, its performance is closely tied to global GDP growth trends, especially in regions where corporate earnings are expanding faster than in the United States. A slowdown in European or Asian growth, or a sharp appreciation of the U.S. dollar, could materially affect returns.

If you want a data-rich, side-by-side comparison of QLTI’s risk-adjusted metrics, ValueRay’s platform offers granular visualizations that can help you assess whether the fund fits your investment thesis.